Humedix, the aesthetics and injectables affiliate of Huons Group, said it has opened registration for its upcoming “HART Symposium,” a major academic symposium for medical professionals to showcase the clinical strengths of its expanding lineup of aesthetic medicine products.

The symposium, set to take place on July 5 at the Grand InterContinental Seoul Parnas, will invite over 120 healthcare professionals, including dermatologists and plastic surgeons, from Korea and abroad.

At the center of this year’s program is Elravie Rituo, a next-generation extracellular matrix (ECM) booster derived from the human acellular dermal matrix (ADM), which has gained rapid clinical traction since its market debut in November 2024.

The symposium will provide in-depth insights into its application in skin rejuvenation procedures, supported by real-world case presentations.

“Through the HART Symposium, we aim to spotlight the clinical value and regenerative potential of Elravie Rituo and provide practitioners with actionable treatment guidance to elevate their practice,” Humedix CEO Kang Min-jong said. “We plan to hold ongoing symposia to ensure physicians stay abreast of the latest techniques and trends in the rapidly evolving field of aesthetics.”

Elravie Rituo is manufactured using Alloclean Technology, a patented tissue processing platform from partner firm L&C Bio. The method preserves the native three-dimensional structure of human tissue while eliminating cells and immunogenic factors, thereby enhancing biocompatibility and safety.

Humedix, under a licensing deal with L&C Bio, holds exclusive sales rights for Elravie Rituo in Korea’s dermatology and aesthetic medical market.

In addition to Elravie Rituo, Humedix will use the symposium to present its broader aesthetic portfolio, which includes the hyaluronic acid-based filler Elravie Premier, the botulinum toxin brand Liztox, the Derma Shine Pro injector system, and CellExosome, an adipose-derived cell culture extract used for skin revitalization.

The symposium’s scientific program will focus on real-world treatment scenarios and clinical best practices. Dr. Park Je-young from Oracle Skin Clinic will chair the symposium, and Dr. Kim Eun-yeon from Beauty Bar Plastic Surgery Clinic and Dr. Kim Sang-yub from JF Dermatology Clinic will deliver case presentations.